COVID-19 vaccine candidates: A review
By:
References
- Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., Bermudez-Gonzalez M., Kleiner G., Aydillo T., Miorin L., Fierer D., et al.: A serological assay to detect SARS-CoV-2 serocon-version in humans. Nat. Med., 2020; 26: 1033–1036
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19. https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html (13.01.2021)
- Baharoon S., Memish Z.A.: MERS-CoV as an emerging respiratory illness: A review of prevention methods. Travel. Med. Infect. Dis., 2019; 32: 101520
- Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., Walmsley S.L., Mazzulli T., Avendano M., Derkach P., Ephtimios I.E., Kitai I., Mederski B.D., Shadowitz S.B., Gold W.L., et al.: Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA, 2003; 289: 2801–2809
- Calina D., Docea A.O., Petrakis D., Egorow A.M., Ishmukhametov A.A., Gabibov A.G., Shtilman M.I., Kostoff R., Carvalho F., Vinceti M., Spandidos D.A., Tsatsakis A.: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (review). Int. J. Mol. Med., 2020; 46: 3–16
- Calina D., Sarkar C., Arsene A.L., Salehi B., Docea A.O., Mondal M., Islam M.T., Zali A., Sharifi-Rad J.: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol. Res., 2020; 68: 315–324
- Callow K.A., Parry H.F., Sergeant M., Tyrrell D.A.: The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect., 1990; 105: 435–446
- Cao W.C., Liu W., Zhang P.H., Zhang F., Richardus J.H.: Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med., 2007; 357: 1162–1163
- ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=Covid19&term=vaccine&cntry=&state=&city=&dist= (15.10.2020)
- Corey L., Mascola J.R., Fauci A.S., Collins F.S.: A strategic approach to COVID-19 vaccine R&D. Science, 2020; 368: 948–950
- Coronavirus. https://www.cdc.gov/coronavirus/types.html (15.10.2020)
- DNA vaccines. https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/vaccines-quality/dna (10.11.2020)
- Draft landscape of COVID-19 candidate vaccines. WHO. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (15.10.2020)
- Du Toit A.: Outbreak of a novel coronavirus. Nat. Rev. Microbiol., 2020; 18: 123
- EMA recommends COVID-19 vaccine Moderna for authorisation in the EU. https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu (13.01.2021)
- Explaining operation warp speed. https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html (13.01.2021)
- Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., Dold C., Faust S.N., Finn A., Flaxman A.L., Hallis B., et al.: Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, 2020; 396: 467–478
- Ge H., Wang X., Yuan X., Xiao G., Wang C., Deng T., Yuan Q., Xiao X.: The epidemiology and clinical information about COVID-19. Eur. J. Clin. Microbiol. Infect. Dis., 2020; 39: 1011–1019
- Graham B.S.: Rapid COVID-19 vaccine development. Science, 2020; 368: 945–946
- Guarner J.: Three emerging coronaviruses in two decades. The story of SARS, MERS, and now COVID-19. Am. J. Clin. Pathol., 2020; 153: 420–421
- Hasson S.S., Al-Busaidi J.K., Sallam T.A.: The past, current and future trends in DNA vaccine immunisations. Asian Pac. J. Trop. Biomed., 2015; 5: 344–353
- Hsu L.Y., Lee C.C., Green J.A., Ang B., Paton N.I., Lee L., Villacian J.S., Lim P.L., Earnest A., Leo Y.S.: Severe acute respiratory syndrome (SARS) in Singapore: Clinical features of index patient and initial contacts. Emerg. Infect. Dis., 2003; 9: 713–717
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020; 395: 497–506
- Huang L., Rong Y., Pan Q., Yi K., Tang X., Zhang Q., Wang W., Wu J., Wanga F.: SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies. Asian J. Pharm. Sci., 2020; doi: 10.1016/j.ajps.2020.08.001
- Hui D.S., Zumla A.: Severe acute respiratory syndrome (SARS): Epidemiology and clinical features. Postgrad. Med. J., 2004; 80: 373–381
- Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html (13.01.2021)
- Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., McDermott A., Flach B., Doria-Rose N.A., et al.: An mRNA vaccine against SARS-CoV-2 – preliminary report. N. Engl. J. Med., 2020; 383: 1920–1931
- Jeyanathan M., Afkhami S., Smaill F., Miller M.S., Lichty B.D., Xing Z.: Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol., 2020; 20: 615–632
- Ki M.: 2015 MERS outbreak in Korea: Hospital-to-hospital transmission. Epidemiol. Health, 2015; 37: e2015033
- Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., et al.: Genomic characterization and epidemiology of 2019 novel corona-virus: Implications for virus origins and receptor binding. Lancet, 2020; 395: 565–574
- Mao R., Qiu Y., He J.S., Tan J.Y., Li X.H., Liang J., Shen J., Zhu L.R., Chen Y., Iacucci M., Ng S.C., Ghosh S., Chen M.H.: Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol., 2020; 5: 667–678
- Masters P.S.: The molecular biology of coronaviruses. Adv. Virus Res., 2006; 66: 193–292
- McBride R., van Zyl M., Fielding B.C.: The coronavirus nucleocapsid is a multifunctional protein. Viruses, 2014; 6: 2991–3018
- Middle East respiratory syndrome coronavirus (MERS-CoV). https://www.who.int/emergencies/mers-cov/en/ (15.10.2020)
- Moderna COVID-19 vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine (13.01.2021)
- Mullard A.: COVID-19 vaccine development pipeline gears up. Lancet, 2020; 395: 1751–1752
- Mullol J., Alobid I., Mariño-Sánchez F., Izquierdo-Domínguez A., Marin C., Klimek L., Wang D.Y., Liu Z.: The loss of smell and taste in the COVID-19 outbreak: A tale of many countries. Curr. Allergy Asthma Rep., 2020; 20: 61
- Neuman B.W., Kiss G., Kunding A.H., Bhella D., Baksh M.F., Connelly S., Droese B., Klaus J.P., Makino S., Sawicki S.G., Siddell S.G., Stamou D.G., Wilson I.A., Kuhn P., Buchmeier M.J.: A structural analysis of M protein in coronavirus assembly and morphology. J. Struct. Biol., 2011; 174: 11–22
- Padron-Regalado E.: Vaccines for SARS-CoV-2: Lessons from other coronavirus strains. Infect. Dis. Ther., 2020; 9: 255–274
- Pardi N., Hogan M.J., Porter F.W., Weissman D.: mRNA vaccines – a new era in vaccinology. Nat. Rev. Drug Discov., 2018; 17: 261–279
- Peeples L.: News feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proc. Natl. Acad. Sci. USA, 2020; 117: 8218–8221
- Peiris J.S.: Coronaviruses. In: Medical microbiology, ed.: D. Greenwood, M. Barer, R. Slack, W. Irving. Churchill Livingstone, Edinburgh 2012, 587–593
- Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from phase 3 study. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against (09.11.2020)
- Project Lightspeed. https://biontech.de/covid-19-portal/project-lightspeed (13.01.2021)
- Romano M., Ruggiero A., Squeglia F., Maga G., Berisio R.: A structural view of SARS-CoV-2 RNA replication machinery: RNA synthesis, proofreading and final capping. Cells, 2020; 9: 1267
- Ruch T.R., Machamer C.E.: The hydrophobic domain of infectious bronchitis virus E protein alters the host secretory pathway and is important for release of infectious virus. J. Virol., 2011; 85: 675–685
- SARS (Severe acute respiratory syndrome). https://www.who.int/ith/diseases/sars/en/ (15.10.2020)
- Satarker S., Nampoothiri M.: Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch. Med. Res., 2020; 51: 482–491
- Schoeman D., Fielding B.C.: Coronavirus envelope protein: Current knowledge. Virol. J., 2019; 16: 69
- Sorbello M., El-Boghdadly K., Di Giacinto I., Cataldo R., Esposito C., Falcetta S., Merli G., Cortese G., Corso R.M., Bressan F., Pintaudi S., Greif R., Donati A., Petrini F.: The Italian coronavirus disease 2019 outbreak: Recommendations from clinical practice. Anaesthesia, 2020; 75: 724–732
- Sternberg A., Naujokat C.: Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sci., 2020; 257: 118056
- Su S., Wong G., Shi W., Liu J., Lai A.C., Zhou J., Liu W., Bi Y., Gao G.F.: Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol., 2016; 24: 490–502
- Tao Y., Shi M., Chommanard C., Queen K., Zhang J., Markotter W., Kuzmin I.V., Holmes E.C., Tong S.: Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history. J. Virol., 2017; 91: e01953–16
- Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., Zhao Y., Li Y., Wang X., Peng Z.: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020; 323: 1061–1069
- Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., et al.: A pneumonia outbreak associated with a new corona-virus of probable bat origin. Nature, 2020; 579: 270–273
DOI: https://doi.org/10.5604/01.3001.0014.7051 | Journal eISSN: 1732-2693
Language: English
Page range: 58 - 63
Submitted on: Dec 6, 2020
Accepted on: Jan 20, 2021
Published on: Feb 3, 2021
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2021 Martyna Biała, Edyta Lelonek, Brygida Knysz, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.